Colin Stephen Magowan

Title: Colin Stephen Magowan: Innovator in Hepatitis B Research

Introduction

Colin Stephen Magowan is a notable inventor based in Bishop, California. He has made significant contributions to the field of biotechnology, particularly in the development of innovative solutions for hepatitis B treatment. With a total of three patents to his name, his work has the potential to impact public health positively.

Latest Patents

Magowan's latest patents include groundbreaking research on adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D. These patents provide non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain. Additionally, they include immunogenic fragments and fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, along with methods of using these fusion proteins.

Career Highlights

Throughout his career, Colin Magowan has worked with prominent organizations in the biotechnology sector. He has been associated with Virion Therapeutics, LLC, and The Wistar Institute, where he has contributed to various research initiatives aimed at advancing medical science.

Collaborations

One of his notable collaborators is Hildegund C. J. Ertl, with whom he has worked on various projects related to his patents and research.

Conclusion

Colin Stephen Magowan's innovative work in the field of hepatitis B research exemplifies the impact of dedicated inventors in advancing medical science. His contributions through patents and collaborations continue to pave the way for new treatments and solutions.